Loratadine
Alavert, Claritin, Loratadine (loratadine) is a small molecule pharmaceutical. Loratadine was first approved as Claritin on 2002-11-27. It is used to treat allergic rhinitis perennial and urticaria in the USA. The pharmaceutical is active against histamine H1 receptor. In addition, it is known to target sodium-dependent neutral amino acid transporter B(0)AT2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Alavert, Claritin, Loratadine, Loratadine redidose (discontinued: Claritin, Loratadine)
CombinationsClaritin, Loratadine pseudoephedrine
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Loratadine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CLARITIN | Bayer | N-019658 OTC | 2002-11-27 | 1 products, RLD, RS |
| CLARITIN HIVES RELIEF | Bayer | N-019658 OTC | 2003-11-19 | 1 products, RLD, RS |
| CLARITIN | Bayer | N-020641 OTC | 2002-11-27 | 1 products, RLD, RS |
| CLARITIN REDITABS | Bayer | N-020704 OTC | 2002-11-27 | 1 products, RLD, RS |
| CLARITIN HIVES RELIEF REDITAB | Bayer | N-020704 OTC | 2003-11-19 | 1 products, RLD, RS |
| CHILDREN'S CLARITIN | Bayer | N-021891 OTC | 2006-08-23 | 1 products, RLD |
| CLARITIN | Bayer | N-021891 OTC | 2018-11-21 | 1 products, RLD, RS |
| CLARITIN | Bayer | N-021952 OTC | 2008-06-16 | 1 products, RLD, RS |
| CLARITIN REDITABS | Bayer | N-021993 OTC | 2006-12-12 | 1 products, RLD, RS |
| ALAVERT | Foundation Consumer Healthcare | N-021375 OTC | 2002-12-19 | 1 products |
Show 1 marketed
Show 2 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 24 / 7 life non-drowsy allergy relief | ANDA | 2024-07-22 |
| 365 whole foods market loratadine | ANDA | 2025-06-11 |
| alavert | New Drug Application | 2025-01-09 |
| all day allergy relief | ANDA | 2024-12-19 |
| allergy | ANDA | 2019-04-30 |
| allergy and congestion relief | ANDA | 2024-02-26 |
| allergy congestion relief | ANDA | 2024-02-27 |
| allergy d | ANDA | 2025-10-03 |
| allergy relief | ANDA | 2025-09-04 |
| allergy relief d | ANDA | 2025-05-28 |
Show 128 more
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
95 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rhinitis | D012220 | EFO_0008521 | J31 | — | 5 | 18 | 13 | 4 | 40 |
| Allergic rhinitis | D065631 | — | J30.9 | — | 5 | 16 | 13 | 3 | 37 |
| Allergic rhinitis seasonal | D006255 | EFO_0003956 | J30 | — | 1 | 11 | 4 | 1 | 17 |
| Allergic rhinitis perennial | D012221 | EFO_1001417 | J30.89 | — | 1 | 3 | 4 | 2 | 10 |
| Healthy volunteers/patients | — | — | — | 3 | — | — | 1 | 4 | 8 |
| Chronic urticaria | D000080223 | — | L50.8 | — | 2 | 1 | 1 | — | 4 |
| Urticaria | D014581 | EFO_0005531 | L50 | — | 1 | 1 | 1 | 1 | 4 |
| Conjunctivitis | D003231 | — | H10 | — | — | 2 | 1 | — | 3 |
| Pruritus | D011537 | — | L29 | — | — | 1 | 1 | 1 | 3 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | 1 | — | 2 |
Show 8 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | 1 | — | 3 | 4 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | 1 | — | 2 | — | — | 3 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | 1 | 2 | 1 | — | — | 3 |
| Asthma | D001249 | EFO_0000270 | J45 | — | 1 | 1 | — | — | 2 |
| Covid-19 | D000086382 | — | U07.1 | — | 2 | 2 | — | — | 2 |
| Seasonal affective disorder | D016574 | — | — | — | — | 1 | — | — | 1 |
| Common cold | D003139 | EFO_0007214 | J00 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 2 | 1 | — | — | 1 | 3 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 2 | — | — | — | 3 |
| Psoriasis | D011565 | EFO_0000676 | L40 | 1 | 1 | — | — | — | 2 |
| Eosinophilic esophagitis | D057765 | EFO_0004232 | K20.0 | — | 1 | — | — | — | 1 |
| Esophagitis | D004941 | HP_0100633 | K20 | — | 1 | — | — | — | 1 |
| Kidney transplantation | D016030 | — | — | — | 1 | — | — | — | 1 |
| Bone nails | D001858 | — | — | — | 1 | — | — | — | 1 |
| Eczema | D004485 | — | L30.9 | — | 1 | — | — | — | 1 |
| Lymphangioleiomyomatosis | D018192 | — | J84.81 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 1 | — | — | — | 1 | 2 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | — | — | — | 1 | 2 |
| Aggression | D000374 | EFO_0003015 | — | 1 | — | — | — | — | 1 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | — | — | — | — | 1 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | 1 | — | — | — | — | 1 |
| Chronic progressive multiple sclerosis | D020528 | EFO_0003840 | — | 1 | — | — | — | — | 1 |
| Sclerosis | D012598 | — | — | 1 | — | — | — | — | 1 |
| Plasma cell neoplasms | D054219 | — | — | 1 | — | — | — | — | 1 |
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | 1 | — | — | — | — | 1 |
| Dermatitis | D003872 | — | L30.9 | 1 | — | — | — | — | 1 |
Show 1 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | — | — | — | — | 1 | 1 |
| Hematologic neoplasms | D019337 | — | — | — | — | — | — | 1 | 1 |
| Bronchial diseases | D001982 | — | — | — | — | — | — | 1 | 1 |
| Cough | D003371 | — | R05 | — | — | — | — | 1 | 1 |
| Iron-deficiency anemia | D018798 | — | D50 | — | — | — | — | 1 | 1 |
| Laryngeal diseases | D007818 | — | J38.7 | — | — | — | — | 1 | 1 |
| Iron deficiencies | D000090463 | — | E61.1 | — | — | — | — | 1 | 1 |
| Chronic cough | D000096822 | — | R05.3 | — | — | — | — | 1 | 1 |
| Disease | D004194 | EFO_0000408 | R69 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Loratadine |
| INN | loratadine |
| Description | Loratadine is a benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders. It has a role as a geroprotector, a H1-receptor antagonist, an anti-allergic agent and a cholinergic antagonist. It is an ethyl ester, a N-acylpiperidine, a tertiary carboxamide, an organochlorine compound and a benzocycloheptapyridine. It is functionally related to a desloratadine. |
| Classification | Small molecule |
| Drug class | tricyclic histaminic-H1 receptor antagonists, loratadine derivatives (formerly-tadine) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 79794-75-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL998 |
| ChEBI ID | — |
| PubChem CID | 3957 |
| DrugBank | DB00455 |
| UNII ID | 7AJO3BO7QN (ChemIDplus, GSRS) |
Target
Alternate
SLC6A15
SLC6A15
Organism
Homo sapiens
Gene name
SLC6A15
Gene synonyms
B0AT2, NTT73, SBAT1
NCBI Gene ID
Protein name
sodium-dependent neutral amino acid transporter B(0)AT2
Protein synonyms
homolog of rat orphan transporter v7-3, orphan sodium- and chloride-dependent neurotransmitter transporter NTT73, orphan transporter v7-3, Sodium- and chloride-dependent neurotransmitter transporter NTT73, Sodium-coupled branched-chain amino-acid transporter 1, sodium/chloride dependent neurotransmitter transporter Homo sapiens orphan neurotransmitter transporter NTT7, solute carrier family 6 (neurotransmitter transporter), member 15, solute carrier family 6 (neutral amino acid transporter), member 15, Solute carrier family 6 member 15, Transporter v7-3
Uniprot ID
Mouse ortholog
Slc6a15 (103098)
sodium-dependent neutral amino acid transporter B(0)AT2 (Q8BG16)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Loratadine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Loratadine
+
Pseudoephedrine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,659 documents
View more details
Safety
Black-box Warning
Black-box warning for: Calmicid ac
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
46,796 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use